UBI4 Antibody

What is UBQLN4 and what are its basic structural characteristics?

UBQLN4 (ubiquilin 4) is a protein regulator of protein degradation that mediates the proteasomal targeting of misfolded, mislocalized or accumulated proteins. In humans, the canonical protein has a reported length of 601 amino acid residues with a molecular mass of 63.9 kDa, though observed molecular weight in laboratory conditions is typically around 70 kDa. The protein is known to have up to two different isoforms reported in scientific literature. UBQLN4's subcellular localization spans multiple cellular compartments including the nucleus, cytoplasmic vesicles, endoplasmic reticulum, and cytoplasm, suggesting diverse functional roles within the cell. The protein is also known by several synonyms in the literature including ataxin-1 ubiquitin-like interacting protein, ataxin-1 ubiquitin-like-interacting protein A1U, connexin43-interacting protein of 75 kDa, and ataxin-1 interacting ubiquitin-like protein.

What is the tissue distribution pattern of UBQLN4 expression?

UBQLN4 demonstrates a distinctive tissue expression profile that varies significantly across different organs and systems. The protein is reported to be highly expressed in the pancreas, kidney, skeletal muscle, heart and throughout various regions of the brain, indicating its potential importance in these metabolically active tissues. Comparatively lower expression levels have been documented in the placenta, lung and liver tissues. This differential expression pattern suggests tissue-specific functions and regulatory mechanisms. Researchers examining UBQLN4 should consider these tissue-specific expression patterns when designing experiments, particularly when selecting appropriate positive controls or when interpreting experimental results across different tissue types.

How does yeast UBI4 compare to human UBQLN4 in structure and function?

The yeast polyubiquitin gene UBI4 encodes a unique precursor protein containing five ubiquitin repeats organized in a head-to-tail arrangement, which represents a fundamental difference from the structure of human UBQLN4. Despite structural differences, both proteins participate in cellular stress response pathways. In yeast, UBI4 has been demonstrated to protect cells against paraquat-induced oxidative stress, where UBI4-deletion (ubi4Δ) leads to observable oxidative stress, apoptotic phenotypes, and significantly decreased replicative lifespan. Experimental evidence shows that the reduced resistance of ubi4Δ cells to paraquat can be rescued through overexpression of either catalase or mitochondrial superoxide dismutase (SOD2), with only SOD2 overexpression successfully restoring the replicative lifespan of ubi4Δ cells. These findings suggest that while the structures differ between yeast and human proteins, the functional involvement in stress response pathways may share evolutionary conservation.

What are the recommended applications and dilutions for UBQLN4 antibodies?

UBQLN4 antibodies can be effectively employed across multiple experimental applications with specific dilution ranges optimized for each technique. For Western Blot (WB) applications, the recommended dilution range is 1:500-1:3000, allowing researchers to detect the protein at its observed molecular weight of approximately 70 kDa in various cell lines including BGC-823, BxPC-3, HeLa, and MKN-45. For Immunohistochemistry (IHC) applications, particularly with human cervical cancer tissue, the recommended dilution range is 1:50-1:500, with suggested antigen retrieval using TE buffer at pH 9.0 (alternatively, citrate buffer at pH 6.0 may be utilized). ELISA represents another validated application for UBQLN4 antibodies. It is important to note that optimal dilutions may be sample-dependent, and researchers are advised to perform preliminary titration experiments within each testing system to achieve optimal results for their specific experimental conditions.

How should researchers validate the specificity of UBQLN4 antibodies?

Validating antibody specificity is crucial for ensuring reliable research outcomes when working with UBQLN4. Researchers should implement a multi-step validation process beginning with positive and negative controls. Positive controls should utilize cell lines with confirmed UBQLN4 expression such as BGC-823, BxPC-3, HeLa, or MKN-45 cells, while UBQLN4 knockout cell lines would serve as ideal negative controls. Western blot analysis should confirm a single band at the expected molecular weight of 70 kDa, with no significant cross-reactivity with other proteins. Researchers should perform peptide competition assays where pre-incubation of the antibody with an excess of the immunizing peptide should eliminate specific binding. Additional validation through multiple detection techniques (e.g., immunoprecipitation followed by mass spectrometry) can provide further confirmation of specificity. For researchers studying UBQLN4 in the context of cancer research, validation in relevant tumor tissue samples with appropriate controls is particularly important given UBQLN4's overexpression in aggressive tumors.

What experimental controls are essential when studying UBQLN4 in cancer contexts?

When investigating UBQLN4 in cancer research contexts, several critical experimental controls must be incorporated to ensure data validity and reproducibility. First, researchers should include matched normal-tumor tissue pairs or normal-malignant cell line comparisons to establish baseline expression differences, as UBQLN4 is known to be overexpressed in aggressive tumors. Positive controls should include cell lines with confirmed high UBQLN4 expression (e.g., specific cancer cell lines like HeLa), while negative controls should include UBQLN4-knockdown or knockout models created through siRNA, shRNA, or CRISPR-Cas9 approaches. When examining UBQLN4's role in double-strand break repair and genome instability, researchers should include controls for DNA damage markers (γ-H2AX) and repair pathway components (homologous recombination vs. nonhomologous end joining). Expression level controls using housekeeping proteins are essential for normalization across samples. Additionally, time-course experiments should be conducted to account for temporal variations in UBQLN4 expression during cellular stress responses or throughout cancer progression stages.

How does UBQLN4 affect DNA damage repair pathways in tumor cells?

UBQLN4 plays a critical role in DNA damage repair mechanisms with significant implications for tumor cell genomic stability and cancer progression. Research has revealed that UBQLN4 specifically inhibits homologous recombination (HR), which is generally considered a more accurate DNA repair pathway, and instead redirects double-strand break (DSB) repair toward nonhomologous end joining (NHEJ), a process more prone to errors. This mechanistic shift results in increased genomic instability, a hallmark of cancer cells that can accelerate tumor evolution and therapeutic resistance. When designing experiments to investigate this phenomenon, researchers should employ DNA damage induction methods (e.g., irradiation, topoisomerase inhibitors, or CRISPR-Cas9 targeted breaks) and measure repair pathway choice using reporter assays specific for HR versus NHEJ pathways. Comparative analyses between UBQLN4-overexpressing and UBQLN4-depleted cancer cells can reveal the extent to which this protein influences repair pathway choice across different cancer types and genetic backgrounds.

What is the relationship between UBQLN4 expression and oxidative stress response?

The relationship between UBQLN4 expression and oxidative stress response appears to be conserved across species, as evidenced by studies in yeast models. In yeast, UBI4 deletion results in increased susceptibility to oxidative stress, manifesting as an apoptotic phenotype and decreased replicative lifespan. Notably, the reduced resistance of UBI4-deficient cells to paraquat-induced oxidative stress can be rescued through overexpression of either catalase or mitochondrial superoxide dismutase (SOD2), suggesting that UBI4 plays a protective role against reactive oxygen species (ROS). The finding that only SOD2 overexpression successfully restored the replicative lifespan of UBI4-deleted cells indicates a potential specific connection between UBI4 and mitochondrial ROS management. Translating these findings to human UBQLN4 research would require experimental designs measuring ROS levels, antioxidant enzyme activities, and markers of oxidative damage in models with manipulated UBQLN4 expression. Researchers could employ fluorescent probes for ROS detection, enzymatic assays for antioxidant activities, and immunoblotting for oxidative stress markers to comprehensively assess how UBQLN4 influences cellular redox homeostasis in human cells.

How can researchers effectively detect polyubiquitylation involving UBI4/UBQLN4?

Detection of polyubiquitylation involving UBI4/UBQLN4 requires specialized techniques due to the complexity of ubiquitin chain configurations and their functional significance. Researchers should consider employing linkage-specific monoclonal antibodies such as HWA4C4, which specifically recognizes K63-linked polyubiquitin chains with high selectivity and no detectable reactivity against other ubiquitin-derived peptides or ubiquitin protein itself. When designing immunodetection experiments, it's important to note that different antibodies may recognize distinct forms of ubiquitin modifications – for example, while P4D1 mAb recognizes all forms of ubiquitin, linkage-specific antibodies provide more precise information about the type of polyubiquitin chain involved. For studying specific polyubiquitination related to UBQLN4, researchers can implement strategies using ectopic expression of ubiquitin mutants (such as K63R-Ub) to block/disrupt specific polyubiquitin chain assemblies and observe the subsequent effects on UBQLN4 function or interaction. This approach allows discrimination between different types of polyubiquitin linkages and their distinct roles in UBQLN4-mediated processes.

What experimental approaches can differentiate between different ubiquitin linkage types in UBQLN4 research?

Differentiating between various ubiquitin linkage types when studying UBQLN4 requires sophisticated experimental approaches that can discriminate the specific lysine residues involved in polyubiquitin chain formation. Researchers should consider a multi-pronged approach beginning with linkage-specific antibodies that can distinguish between K6-, K11-, K27-, K29-, K33-, K48-, and K63-linked polyubiquitin chains. For example, the HWA4C4 monoclonal antibody has been demonstrated to specifically recognize K63-linked polyubiquitin without cross-reactivity with other linkage types. Complementary approaches include using ubiquitin mutants where specific lysine residues are mutated to arginine (e.g., K63R-Ub) to block chain extension at those sites, allowing researchers to observe the functional consequences of disrupting specific linkage types. Mass spectrometry-based approaches can provide detailed identification and quantification of linkage-specific ubiquitylation sites. For cell-based studies, immunofluorescence experiments using linkage-specific antibodies can reveal the subcellular localization patterns of different polyubiquitin chain types and their colocalization with UBQLN4, offering insights into spatially distinct functions of different ubiquitin linkage types in UBQLN4-mediated processes.

What methodological considerations are important when analyzing UBQLN4's role in proteasomal targeting?

When analyzing UBQLN4's role in proteasomal targeting of misfolded or mislocalized proteins, researchers must implement methodologies that can effectively track protein degradation pathways and distinguish between proteasomal and non-proteasomal degradation mechanisms. A comprehensive experimental approach should include pulse-chase experiments using metabolic labeling to track protein turnover rates in cells with normal versus altered UBQLN4 expression levels. Researchers should employ proteasome inhibitors (e.g., MG132, bortezomib) to determine the proteasome-dependence of UBQLN4-mediated protein degradation, while autophagy inhibitors (e.g., bafilomycin A1, chloroquine) can help distinguish between these two major degradation pathways. Co-immunoprecipitation experiments are essential to identify direct interactions between UBQLN4 and potential substrate proteins or components of the ubiquitin-proteasome system. Live-cell imaging using fluorescently tagged UBQLN4 and proteasome components can provide dynamic information about recruitment and colocalization during stress conditions or when misfolded proteins accumulate. When designing these experiments, researchers should consider cell-type specific differences in proteostasis networks and include appropriate controls for different stress conditions that might influence UBQLN4's function in protein quality control.

How can researchers troubleshoot non-specific binding when using UBQLN4 antibodies?

When encountering non-specific binding issues with UBQLN4 antibodies, researchers should implement a systematic troubleshooting approach focusing on antibody specificity and experimental conditions. First, optimize blocking procedures by testing different blocking agents (BSA, non-fat dry milk, commercial blocking buffers) at various concentrations (3-5%) and incubation times (1-2 hours at room temperature or overnight at 4°C). Increase the stringency of wash steps by adding additional detergent (0.1-0.5% Tween-20 or Triton X-100) to wash buffers and extending washing duration. Titrate primary antibody concentrations, starting with the manufacturer's recommended dilution range (1:500-1:3000 for WB, 1:50-1:500 for IHC) and adjusting as needed based on signal-to-noise ratio. Consider pre-adsorption of the antibody with non-specific proteins or tissue lysates from species similar to your experimental samples. For Western blots specifically, ensure proper sample preparation by including protease inhibitors during lysis, optimizing protein loading (20-50 μg typically), and carefully controlling transfer conditions. If problems persist, consider implementing a peptide competition assay where pre-incubating the antibody with its immunizing peptide should eliminate specific binding but not non-specific binding.

What are the recommended protocols for antigen retrieval when using UBQLN4 antibodies in immunohistochemistry?

Effective antigen retrieval is critical for successful immunohistochemical detection of UBQLN4 in fixed tissue samples. The primary recommended protocol involves heat-induced epitope retrieval (HIER) using TE buffer at pH 9.0, which has been validated for optimal UBQLN4 detection in human cervical cancer tissue. This alkaline pH buffer effectively breaks protein cross-links formed during fixation while maintaining tissue morphology. The procedure should include bringing the buffer to a boil, immersing the slides, maintaining at a sub-boiling temperature (95-98°C) for 15-20 minutes, followed by cooling to room temperature for 20 minutes. Alternatively, researchers may employ citrate buffer at pH 6.0 following a similar heating protocol if TE buffer yields suboptimal results with particular tissue types. When troubleshooting, researchers should systematically vary key parameters including buffer composition, pH (ranging from 6.0 to 9.0), heating method (microwave, pressure cooker, or water bath), and duration (10-30 minutes). Each tissue type may require optimization, with formalin-fixed samples typically requiring more aggressive retrieval than frozen sections. Following antigen retrieval, a thorough PBS wash and appropriate blocking step are essential before primary antibody application.

How can UBQLN4 antibodies be used to investigate its role in genome instability and carcinogenesis?

UBQLN4 antibodies provide powerful tools for investigating the protein's role in genome instability and carcinogenesis through multiple experimental approaches targeting its effects on DNA repair mechanisms. Researchers can utilize UBQLN4 antibodies in immunoblotting analyses to compare expression levels between normal and cancer tissues or cell lines, establishing correlations between UBQLN4 overexpression and tumor aggressiveness. Chromatin immunoprecipitation (ChIP) assays using UBQLN4 antibodies can identify potential interactions between UBQLN4 and chromatin at sites of DNA damage. Immunofluorescence microscopy with UBQLN4 antibodies enables visualization of UBQLN4 recruitment to DNA damage sites, particularly when co-stained with γ-H2AX or other DNA damage markers. Researchers should design experiments to measure the impact of UBQLN4 expression levels on homologous recombination versus nonhomologous end joining repair pathway choice, using reporter assays and immunofluorescence detection of pathway-specific factors. Co-immunoprecipitation experiments can identify UBQLN4's protein interaction network specifically in cancer contexts, potentially revealing cancer-specific binding partners that contribute to genome instability.

What experimental designs can quantify the relationship between UBQLN4 and cellular stress response?

To quantify the relationship between UBQLN4 and cellular stress response, researchers should implement multi-parametric experimental designs that capture both UBQLN4 dynamics and stress-related cellular outcomes. Time-course experiments tracking UBQLN4 expression, localization, and post-translational modifications following exposure to various stressors (oxidative stress, heat shock, ER stress, DNA damage) provide valuable insights into the kinetics of UBQLN4's stress response. Flow cytometry analysis using fluorescently-labeled UBQLN4 antibodies can quantify changes in protein levels across cell populations under stress conditions. For oxidative stress specifically, researchers should measure reactive oxygen species (ROS) levels using fluorescent probes while simultaneously assessing UBQLN4 expression or localization changes. Gain-of-function and loss-of-function approaches (overexpression, knockdown, or knockout of UBQLN4) followed by stress exposure and measurement of cell viability, apoptosis markers, and stress-responsive gene expression can establish causative relationships. Drawing from yeast UBI4 research, experimental designs should include assessments of how UBQLN4 manipulation affects antioxidant enzyme activities (particularly catalase and SOD2) and cellular lifespan metrics, as these connections have been established in the evolutionary related yeast system.

What are the emerging research questions regarding UBQLN4's role in disease processes?

The current understanding of UBQLN4 points to several critical emerging research questions that require further investigation. Given UBQLN4's established role in redirecting double-strand break repair from homologous recombination to nonhomologous end joining and its overexpression in aggressive tumors, a key question is whether UBQLN4 inhibition could enhance the efficacy of DNA-damaging cancer therapies or reduce genomic instability that drives tumor evolution. The potential relationship between UBQLN4 and oxidative stress response, as suggested by findings from yeast UBI4 studies, raises important questions about whether UBQLN4 functions similarly in human cells to protect against oxidative damage, and how this might influence age-related diseases and neurodegeneration. Additional research questions include: how UBQLN4's interaction with the proteasomal system influences the selective degradation of specific protein substrates; whether UBQLN4 expression or function is regulated by specific cellular stressors; and how UBQLN4's tissue-specific expression patterns relate to tissue-specific disease manifestations. These emerging questions represent important directions for researchers utilizing UBQLN4 antibodies in various experimental systems.

What methodological advances would enhance UBQLN4/UBI4 antibody research?

Advancing UBQLN4/UBI4 antibody research would benefit significantly from several methodological innovations that address current technical limitations. Development of linkage-specific antibodies for different types of polyubiquitin chains associated with UBQLN4, similar to the HWA4C4 mAb specific for K63-linked polyubiquitin, would enable more precise characterization of UBQLN4's role in protein degradation pathways. Creation of isoform-specific antibodies would help clarify the potential functional differences between the reported UBQLN4 isoforms. Advanced live-cell imaging techniques utilizing UBQLN4 antibody-based fluorescent probes would allow real-time visualization of UBQLN4 dynamics during stress responses or cell cycle progression. Advances in proximity-labeling techniques combined with mass spectrometry would facilitate comprehensive mapping of the UBQLN4 interactome under various physiological and pathological conditions. Development of tissue-clearing techniques compatible with UBQLN4 immunostaining would enable three-dimensional visualization of UBQLN4 distribution in intact tissues or organoids. Creation of conformation-specific antibodies could potentially distinguish between different functional states of UBQLN4. These methodological advances would collectively enhance researchers' ability to investigate the complex roles of UBQLN4 in normal physiology and disease processes.

Validated Detection Applications and Conditions for UBQLN4 Antibodies